FACTOID # 24: You're 66 times more likely to be prosecuted in the USA than in France
 
 Home   Encyclopedia   Statistics   Countries A-Z   Flags   Maps   Education   Forum   FAQ   About 
 
WHAT'S NEW
RECENT ARTICLES
More Recent Articles »
 

FACTS & STATISTICS    Simple view

  1. Select countries to view: (hold down Control key and click to select several)

     

     

    Compare:

     

     
  1. Select fact or statistic: (* = graphable)

     

     

     

  2. (OPTIONAL) Compare to statistic: (both need to be graphable)

     

     

     

  3. View result as:

     

       
(OR) SEARCH ALL encyclopedia, stats & forums:   

Encyclopedia > Dendreon
This article or section needs to be updated.
Parts of this article or section have been identified as no longer being up to date.
Please update the article to reflect recent events, and remove this template when finished.

Dendreon is a Seattle based biotechnology company. Its leading product candidate, Sipuleucel-T (known as Provenge during drug trials), is an immunotherapy for prostate cancer. The FDA advisory committee on March 29 2007 voted 17-0 that Provenge is reasonably safe and 13-4 that the trial data showed substantial evidence that it is effective.[1] Image File history File links Current_event_marker. ... Image File history File links Nuvola_apps_important. ... City nickname Emerald City City bird Great Blue Heron City flower Dahlia City mottos The City of Flowers The City of Goodwill City song Seattle, the Peerless City Mayor Greg Nickels County King County Area   - Total   - Land   - Water   - % water 369. ... The structure of insulin Biotechnology is technology based on biology, especially when used in agriculture, food science, and medicine. ... Dendreon is a Seattle based biotechnology company. ... Dendreon is a Seattle based biotechnology company. ... Immunotherapy is a form of medical treatment based upon the concept of modulating the immune system to achieve a therapeutic goal. ... Prostate cancer is a disease in which cancer develops in the prostate, a gland in the male reproductive system. ...


In his February 18, 2005 column in Forbes magazine, Dr. Scott Gottlieb, who later served as a top policy maker with the FDA until early 2007, argued for Provenge approval: "That 4.5-month increase in survival is almost double the 2.5-month benefit shown in clinical trials of Taxotere, a drug that is the next best thing for patients like those in the Provenge trial whose cancer has spread beyond the prostate gland and is no longer being controlled by hormonal therapy."[2] This article or section does not adequately cite its references or sources. ... Docetaxel is a clinically well established anti-neoplastic medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. ...


In 2006, the company built a manufacturing facility in Hanover, New Jersey to accomodate Provenge production in anticipation of possible FDA approval in 2007, as well as for production for a Phase III trial, IMPACT (previously known as D9902B)[3]. Hanover Township is a township located in Morris County, New Jersey. ... The United States Food and Drug Administration is the government agency responsible for regulating food, dietary supplements, drugs, cosmetics, medical devices, biologics and blood products in the United States. ...


In January 2007, the FDA accepted Dendreon's Biologics License Application filing for Provenge, with an FDA decision due by May 15, 2007. [4] BLA is a Three Letter Acronym that could mean: Black Light Activists [1] Bachelor of Liberal Arts Baltimore and Annapolis Railroad (AAR reporting marks BLA) Balochistan Liberation Army Barcelona, Venezuela airport – IATA airport code BLA Bavarian Liberation Army β-lactamase Black Liberation Army Business Licensing Authority [2] Siksika language – ISO 639...


In March 2007, the FDA's Office of Cellular, Tissue and Gene Therapies Advisory Committee voted 17-0 in favor of the safety of Provenge and 13-4 in favor of the efficacy of Provenge. The FDA has a set a PDUFA date of May 15, 2007 as its deadline to decide whether or not to grant approval to Provenge. The FDA is not bound to accept the recommendation of the advisory committee. [5]


References

  1. ^ "US panel: Dendreon cancer therapy appears to work", Reuters via Yahoo! News, Mar 29, 2007.
  2. ^ Dr.Scott Gottlieb. "Prostate Drug Promise Vs. FDA Rigidity", Forbes, February 18, 2005.
  3. ^ Luke Timmerman. "Building factory a balancing act for Dendreon", Seattle Times, August 9, 2006.
  4. ^ Adam Feuerstein (March 16, 2007). Dendreon's Date with Destiny. thestreet.com.
  5. ^ Dendreon Investor Relations (March 29, 2007). Dendreon Announces FDA Advisory Committee Reviewed Provenge for Hormone Refractory Prostate Cancer. dendreon.com.

External links

  • Company web site
  • "Dendreon: New Weapon Against Tumors", Gene Marichal, BusinessWeek, Oct 6, 2003

 

COMMENTARY     


Share your thoughts, questions and commentary here
Your name
Your comments
Please enter the 5-letter protection code

Want to know more?
Search encyclopedia, statistics and forums:
 


Lesson Plans | Student Area | Student FAQ | Reviews | Press Releases |  Feeds | Contact
The Wikipedia article included on this page is licensed under the GFDL.
Images may be subject to relevant owners' copyright.
All other elements are (c) copyright NationMaster.com 2003-5. All Rights Reserved.
Usage implies agreement with terms.